Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) Debt to Equity (2023 - 2026)

Cannabis Bioscience International Holdings filings provide 4 years of Debt to Equity readings, the most recent being -$0.18 for Q1 2026.

  • On a quarterly basis, Debt to Equity rose 31.64% to -$0.18 in Q1 2026 year-over-year; TTM through Feb 2026 was -$0.18, a 31.64% increase, with the full-year FY2025 number at -$0.23, up 1.79% from a year prior.
  • Debt to Equity reached -$0.18 in Q1 2026 per CBIH's latest filing, up from -$0.19 in the prior quarter.
  • The five-year high for Debt to Equity was -$0.18 in Q1 2026, with the low at -$0.45 in Q2 2023.
  • A 4-year average of -$0.25 and a median of -$0.23 in 2024 define the central range for Debt to Equity.
  • Year-over-year, Debt to Equity soared 48.22% in 2024 and then fell 0.18% in 2025.
  • Year by year, Debt to Equity stood at -$0.31 in 2023, then increased by 25.1% to -$0.23 in 2024, then rose by 16.75% to -$0.19 in 2025, then grew by 7.08% to -$0.18 in 2026.
  • Per Business Quant, the three most recent readings for CBIH's Debt to Equity are -$0.18 (Q1 2026), -$0.19 (Q4 2025), and -$0.2 (Q3 2025).